对AMBASSADOR试验的反思：辅助派姆单抗在肌肉侵袭性尿路上皮癌中的作用

IF 11.7 1区医学 Q1 CELL BIOLOGY

Cell Reports Medicine Pub Date : 2024-12-17 DOI:10.1016/j.xcrm.2024.101873

Pietro Scilipoti, Marco Moschini, Alberto Briganti

{"title":"对AMBASSADOR试验的反思：辅助派姆单抗在肌肉侵袭性尿路上皮癌中的作用","authors":"Pietro Scilipoti, Marco Moschini, Alberto Briganti","doi":"10.1016/j.xcrm.2024.101873","DOIUrl":null,"url":null,"abstract":"Recent advances in immunotherapy have transformed treatment for muscle-invasive urothelial carcinoma, providing hope for cisplatin-ineligible patients. The AMBASSADOR trial evaluated adjuvant pembrolizumab in high-risk patients post-surgery, demonstrating improved disease-free survival. As overall survival data evolve, pembrolizumab is emerging as a promising adjuvant treatment option, complementing existing therapies in the treatment landscape for this disease.","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":"5 12","pages":"101873"},"PeriodicalIF":11.7000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722087/pdf/","citationCount":"0","resultStr":"{\"title\":\"Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinoma.\",\"authors\":\"Pietro Scilipoti, Marco Moschini, Alberto Briganti\",\"doi\":\"10.1016/j.xcrm.2024.101873\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Recent advances in immunotherapy have transformed treatment for muscle-invasive urothelial carcinoma, providing hope for cisplatin-ineligible patients. The AMBASSADOR trial evaluated adjuvant pembrolizumab in high-risk patients post-surgery, demonstrating improved disease-free survival. As overall survival data evolve, pembrolizumab is emerging as a promising adjuvant treatment option, complementing existing therapies in the treatment landscape for this disease.\",\"PeriodicalId\":9822,\"journal\":{\"name\":\"Cell Reports Medicine\",\"volume\":\"5 12\",\"pages\":\"101873\"},\"PeriodicalIF\":11.7000,\"publicationDate\":\"2024-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722087/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell Reports Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.xcrm.2024.101873\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xcrm.2024.101873","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

免疫疗法的最新进展已经改变了肌肉侵袭性尿路上皮癌的治疗方法，为不适合顺铂治疗的患者提供了希望。AMBASSADOR试验评估了高风险患者术后的辅助派姆单抗，显示出无病生存期的改善。随着总体生存数据的发展，派姆单抗正成为一种有希望的辅助治疗选择，补充了该疾病治疗领域的现有疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinoma.

Recent advances in immunotherapy have transformed treatment for muscle-invasive urothelial carcinoma, providing hope for cisplatin-ineligible patients. The AMBASSADOR trial evaluated adjuvant pembrolizumab in high-risk patients post-surgery, demonstrating improved disease-free survival. As overall survival data evolve, pembrolizumab is emerging as a promising adjuvant treatment option, complementing existing therapies in the treatment landscape for this disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cell Reports Medicine Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

15.00

自引率

1.40%

发文量

231

审稿时长

40 days

期刊介绍： Cell Reports Medicine is an esteemed open-access journal by Cell Press that publishes groundbreaking research in translational and clinical biomedical sciences, influencing human health and medicine. Our journal ensures wide visibility and accessibility, reaching scientists and clinicians across various medical disciplines. We publish original research that spans from intriguing human biology concepts to all aspects of clinical work. We encourage submissions that introduce innovative ideas, forging new paths in clinical research and practice. We also welcome studies that provide vital information, enhancing our understanding of current standards of care in diagnosis, treatment, and prognosis. This encompasses translational studies, clinical trials (including long-term follow-ups), genomics, biomarker discovery, and technological advancements that contribute to diagnostics, treatment, and healthcare. Additionally, studies based on vertebrate model organisms are within the scope of the journal, as long as they directly relate to human health and disease.